An up-and-coming stock with lots of potential is Viking Therapeutics (NASDAQ: VKTX). Investors have been piling money into the biotech stock this year, as it has surged 150% since January. And at a valuation of just $2.3 billion, it still isn't terribly big.

Can investing in the business today help make you a millionaire?

One of the key reasons investors are bullish on Viking's prospects is that it has a promising asset in VK2809. It's a treatment for non-alcoholic steatohepatitis (NASH) -- liver inflammation. At its peak, analysts believe it may generate up to $3.6 billion in annual revenue, easily making it a blockbuster drug. 

Continue reading

Source Fool.com